collaboration

The companies will use Natera's Signatera circulating tumor DNA assay to assess response to NEO-PV-01, a clinical trial-stage neoantigen cancer vaccine.

The collaboration agreement includes support for development, regulatory submission, and commercialization of tests to guide use of Novartis' drug portfolio.

The companies plan to combine Nashville's BioVU biobank of 250,000 DNA samples and 2.8 million patient records with GeneWiz's sequencing services.

The new RNA sequencing analysis workflow integrates Roche's RNA-seq library kits with Genialis' automated data processing pipeline for gene expression analyses.

The Lantern Project will screen for patients who may be suffering from Gaucher disease, Fabry disease, Pompe disease, MPS I, or ASMD, and offer confirmatory DNA testing.

The analytics firm formerly known as Quintiles IMS will offer researchers secure access to Genomics England's de-identified databases in pursuit of precision medicine.

The blood-based test, called Melaseq, measures 38 circulating microRNAs that regulate processes that melanoma cells undergo as they become malignant.

Archer will develop and pursue regulatory approval for a companion diagnostic that will help find patients who may benefit from one of Merck's drug candidates.

The collaboration will focus on the development of a bespoke silicon array to enable high-throughput production of high-fidelity gene-length DNA.

THL Biobank will add datasets from approximately 150,000 donors, including multi-omic cohorts, to the larger network.

Pages

This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.

The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.

Researchers find that people's genetics influence their success at university, but that it is not the only factor.

In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.